Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Cholangiocarcinoma × pemigatinib × Clear all

Phase

Phase 2 6 Phase 1 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 1

Interventions

Gemcitabine 15 Cisplatin 10 Oxaliplatin 8 Capecitabine 7 Leucovorin 6 Fluorouracil 5 pembrolizumab 4 Irinotecan 3 ivosidenib 2 Photochemotherapy 2 Cholangiopancreatography, Endoscopic Retrograde 2 zanidatamab 1 toripalimab 1 pemigatinib 1 lenvatinib 1 infigratinib 1 durvalumab 1 cemiplimab 1 becatecarin 1 atezolizumab 1 Tissue Adhesives 1 Tegafur 1 S 1 (combination) 1 Radiotherapy, Image-Guided 1 Radiation 1 Pancreaticojejunostomy 1 Nivolumab 1 Neoadjuvant Therapy 1 Ipilimumab 1 Injections 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03656536 2025-08-24

FIGHT-302

Incyte Corporation

Phase 3 Terminated

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡